
Sign up to save your podcasts
Or


ETF Trends CEO Tom Lydon discussed the Virtus LifeSci Biotech Clinical Trials ETF (BBC) on this week’s “ETF of the Week” podcast with Chuck Jaffe on the MoneyLife Show.
BBC seeks investment results that correspond to the performance of the BioShares Biotechnology Clinical Trials Index. Clinical Trials stage companies are typically younger, smaller companies which do not have a drug approved, but instead focus on testing their experimental drugs.
By VettaFi4.5
1818 ratings
ETF Trends CEO Tom Lydon discussed the Virtus LifeSci Biotech Clinical Trials ETF (BBC) on this week’s “ETF of the Week” podcast with Chuck Jaffe on the MoneyLife Show.
BBC seeks investment results that correspond to the performance of the BioShares Biotechnology Clinical Trials Index. Clinical Trials stage companies are typically younger, smaller companies which do not have a drug approved, but instead focus on testing their experimental drugs.

4,091 Listeners

274 Listeners

522 Listeners

294 Listeners

936 Listeners

194 Listeners

65 Listeners

596 Listeners

907 Listeners

208 Listeners

411 Listeners

161 Listeners

66 Listeners

310 Listeners

39 Listeners